STOCK TITAN

Moderna (MRNA) Stock Price, News & Analysis

MRNA NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
67 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+177% close of August 19, 2026
1-year change
+772.1% closing prices, November 20, 2025 to November 20, 2026
1-month change
-19.4% closing prices, October 20, 2026 to November 20, 2026

Company Description

Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on messenger RNA (mRNA) medicine. The company describes itself as a pioneer and leader in this field, using its mRNA technology platform to rethink how medicines are made and to transform how diseases are treated and prevented. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases, latent and other virus vaccines, and autoimmune diseases.

According to its public disclosures, Moderna has evolved into a commercial-stage company with multiple approved products and an extensive development pipeline. Its first commercial product was Spikevax, an mRNA COVID-19 vaccine that became one of the earliest and widely used COVID vaccines. The company later received approval for mRESVIA, its respiratory syncytial virus (RSV) vaccine for older adults and certain high-risk adults, and for mNEXSPIKE, a new COVID-19 vaccine. These products form the foundation of Moderna’s respiratory vaccines portfolio and underpin its seasonal vaccine franchise targeting at-risk populations.

Moderna reports that its mRNA platform supports four main franchises: respiratory virus vaccines, latent and other virus vaccines, oncology therapeutics, and rare disease therapeutics. The company has described a diverse and extensive development pipeline, with dozens of development candidates and programs in clinical studies. Its programs span infectious diseases, immuno-oncology, cardiovascular and rare genetic diseases, among other areas, reflecting the breadth of applications the company sees for mRNA technology.

Business focus and strategy

In its investor and proxy materials, Moderna outlines a strategy centered on three priorities: driving sales of its marketed products, advancing additional mRNA products to approval, and improving cost efficiency across the business. The company highlights Spikevax, mRESVIA and mNEXSPIKE as the commercial base of a seasonal vaccine franchise, and it is also pursuing regulatory approvals for additional candidates such as a seasonal influenza vaccine (mRNA-1010), a flu/COVID combination vaccine (mRNA-1083), and a Norovirus vaccine (mRNA-1403). These efforts are intended to expand its respiratory portfolio beyond COVID-19.

Beyond infectious disease, Moderna is investing in oncology therapeutics and rare disease therapeutics. For example, the company is advancing mRNA-4157 (intismeran autogene) in collaboration with Merck in multiple Phase 2 and Phase 3 clinical trials across tumor types such as melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma. It is also developing mRNA-4359, an investigational mRNA-based therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells, in a Phase 1/2 study that includes cohorts in metastatic melanoma and metastatic non-small cell lung cancer.

In rare diseases, Moderna is studying mRNA-3927 as a therapeutic candidate for propionic acidemia (PA) in a registrational study, and mRNA-3705 as a therapeutic candidate for methylmalonic acidemia (MMA), which has been selected by the U.S. Food and Drug Administration for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program with a registrational study expected to begin based on agreed design. These programs illustrate how the company is applying its mRNA platform to inherited metabolic disorders.

Manufacturing and operational footprint

Moderna describes a global manufacturing network built around its mRNA platform. In the United States, the company’s facility in Norwood, Massachusetts, is used for scalable, end-to-end production of mRNA medicines and incorporates automation, robotics and AI to increase cost efficiency and reduce waste. The company has announced the onshoring of Drug Product manufacturing to this site, which it states will complete full end-to-end manufacturing for its mRNA medicines in the U.S.

Outside the U.S., Moderna has added company-built and managed facilities in Laval, Canada; Harwell, United Kingdom; and Clayton, Australia. These sites are intended to enable local access to mRNA medicines and support revenue diversification. The company has also referenced manufacturing and R&D facilities that have received licenses from regulators such as the UK Medicines and Healthcare products Regulatory Agency and Australia’s Therapeutic Goods Administration. Together, these facilities form a global production network that supports commercial supply, multi-year strategic partnerships, and clinical development.

Financial framework and capital structure

Moderna communicates a multi-year financial framework that includes a target of reaching cash breakeven on a cash cost basis by 2028. The company has reported that, in the post-pandemic endemic COVID-19 market, expenses have exceeded revenues in recent years and it anticipates net losses over certain periods as it invests in its pipeline. To support its plans, Moderna has focused on cost reductions in research and development, selling, general and administrative expenses, and cost of goods, including procurement savings, manufacturing efficiencies and headcount reductions.

In November 2025, Moderna entered into a Credit and Guaranty Agreement providing for a credit facility of up to $1.5 billion, consisting of an initial term loan and delayed draw term loans. The loans are guaranteed by certain subsidiaries and secured by an all-asset collateral grant, subject to customary exceptions and limitations. The agreement includes a minimum liquidity covenant based on cash and cash equivalents, with thresholds that can change depending on the amount drawn and the company’s market capitalization. This facility is described as non-dilutive financing that bolsters the company’s balance sheet and provides additional flexibility.

Pipeline and development highlights

Moderna regularly reports on its late-stage pipeline and approved product milestones. In respiratory vaccines, the company notes that Spikevax is approved in multiple countries, mNEXSPIKE has received approvals in the U.S. and Canada and has been filed in additional markets, and mRESVIA is approved in many countries for adults aged 60 and older and, in a subset of those countries, for certain adults aged 18–59 at increased risk. The company is pursuing approvals for mRNA-1010 in the U.S., European Union, Canada and Australia, and its mRNA-1083 flu/COVID combination vaccine has filings under review with regulators such as the European Medicines Agency and Health Canada.

For Norovirus, Moderna is conducting a Phase 3 study of mRNA-1403, enrolling across multiple respiratory seasons to accrue sufficient cases, with an interim analysis expected based on trial progress. In pandemic influenza, the Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to invest up to $54.3 million to support a pivotal Phase 3 trial of Moderna’s H5 pandemic influenza vaccine candidate, mRNA-1018, with the goal of advancing it toward licensure and enhancing global pandemic preparedness.

In oncology, mRNA-4157 (intismeran autogene) is being studied in multiple Phase 2 and Phase 3 trials across several tumor types, including adjuvant melanoma and non-small cell lung cancer, as well as bladder and renal cell carcinoma. The company has indicated that some of these studies are fully enrolled and others are actively enrolling. mRNA-4359 has generated Phase 1b data presented at a major oncology congress, and the Phase 2 portion of its study is enrolling patients in metastatic melanoma and metastatic non-small cell lung cancer.

In rare diseases, Moderna has presented data suggesting that mRNA-3927 has been generally well tolerated to date in clinical studies for propionic acidemia, with trial participants electing to continue in an open-label extension. For mRNA-3705 in methylmalonic acidemia, the company has shared interim Phase 1/2 data and is working with regulators on a pivotal study design under the FDA’s START program.

Corporate governance and shareholder matters

Moderna is incorporated as Moderna, Inc. and files reports with the U.S. Securities and Exchange Commission (SEC), including Forms 8-K and proxy statements. In 2025, the company called a Special Meeting of Shareholders to consider, among other items, a one-time stock option exchange program for non-Executive Committee employees. The program allows eligible employees to exchange underwater stock options—those with exercise prices significantly above the market price—for new options with fewer shares, a new exercise price equal to fair market value on the grant date, and new vesting terms. Executive Committee members, consultants, advisors and directors are excluded from participation.

The company states that this option exchange is intended to restore equity value for non-Executive Committee employees, increase retention and motivation, and better align employee and shareholder interests while being designed to be fair-value neutral and anti-dilutive to shareholders. The proposal was approved by shareholders, according to the reported voting results.

Company mission and culture

Across its public communications, Moderna emphasizes its mission to deliver the greatest possible impact to people through mRNA medicines. The company highlights a global team and a culture driven by its values and mindsets, and notes recognition in industry rankings as a biopharmaceutical employer. Moderna describes its work as operating at the intersection of science, technology and health, with the aim of developing medicines at speed and scale for a range of serious diseases.

Key segments and focus areas

  • Respiratory virus vaccines: COVID-19 vaccines (Spikevax, mNEXSPIKE), RSV vaccine (mRESVIA), seasonal influenza vaccine candidate (mRNA-1010), flu/COVID combination vaccine candidate (mRNA-1083), and Norovirus vaccine candidate (mRNA-1403).
  • Latent and other virus vaccines: Programs targeting viruses such as cytomegalovirus (CMV) have been part of the portfolio, with certain programs discontinued or refocused based on clinical results and strategic prioritization.
  • Oncology therapeutics: Personalized and antigen-based mRNA cancer therapies including mRNA-4157 (intismeran autogene) and mRNA-4359 in multiple tumor types and stages.
  • Rare disease therapeutics: mRNA-based treatments for inherited metabolic disorders, including propionic acidemia (mRNA-3927) and methylmalonic acidemia (mRNA-3705), progressing through clinical development.

Moderna’s disclosures indicate that it continues to refine its pipeline, discontinuing some programs that do not meet efficacy or strategic thresholds while concentrating resources on late-stage and high-priority candidates in infectious disease, oncology and rare diseases.

Stock Performance

$199.30
+2.21%
+4.30
After hoursChange vs the $195.00 closeLast updated: at
+772.1%
Performance 1 year
$80.6B
404.6M
Shares outstanding As of October 30, 2026.

Moderna (MRNA) closed at $195.00 on November 20, 2026. Over the past 12 months, the price has gained 772.1%.

See what a $1,000 investment in MRNA would be worth today

Average down calculator for MRNA

MRNA Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Moderna has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include covid-19, conferences, earnings, clinical trial, earnings date. View all MRNA news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
275,626
Shares Sold
12
Transactions
Most Recent Transaction
Hoge Stephen (President) sold 39,215 shares at an average of $211.61 on November 17, 2026

Insider selling at Moderna over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Moderna generated $1.9B in revenue in FY2025, retaining a 55.4% gross margin, operating income reached -$3.1B, and net income was -$2.8B. Diluted earnings per share stood at -$7.26. The company generated -$1.9B in operating cash flow. The current ratio was 3.29, measuring current assets divided by current liabilities.

$1.9B
Revenue (FY2025)
-$2.8B
Net Income (FY2025)
-$1.9B
Operating Cash Flow

Upcoming Events

DEC
12
December 12, 2026 Clinical

mRNA-2808 ASH presentation

Oral presentation at ASH on Dec 12, 2026 with updated Phase 1/2 MyEngage mRNA-2808 data; webcast/details to be announced.
JAN
01
January 1, 2027 - December 31, 2028 Product

Potential product launches

Potential product launches across infectious diseases, intismeran and rare diseases in 2027–2028; CCO to lead rollouts.
OCT
2027
October 2027 Product

mFLUSIVA launch

Broad mFLUSIVA commercial launch during the 2027–2028 respiratory season; rollout across markets as outlined at Analyst Day.
YEAR
2028
2028 Financial

Cash breakeven target

Company aims to achieve cash breakeven by end of 2028 per JPM presentation.
MAR
01
March 1, 2032 Financial

Convertible Notes Maturity

Maturity of $2.6B 0.00% Convertible Senior Notes due March 1, 2032; senior unsecured notes with conversion and capped-call features.

Moderna has 5 upcoming scheduled events. The next event, "mRNA-2808 ASH presentation", is scheduled for December 12, 2026 (in 20 days). 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the MRNA stock price.

Short Interest History

Last 12 Months

Short interest in Moderna (MRNA) currently stands at 33.2 million shares, up 1.8% from the previous reporting period, representing 8.8% of the float. Since November 2025, short interest has decreased by 51.2%.

Days to Cover History

Last 12 Months

Days to cover for Moderna (MRNA) currently stands at 1.8 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 75.8%. Across the settlements charted above, it has ranged from 1.0 to 12.3 days.

MRNA Company Profile & Sector Positioning

Moderna (MRNA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing MRNA often look at related companies in the same sector, including Regeneron Pharmaceuticals Inc (REGN), argenx SE (ARGX), Vertex Pharmaceuticals Inc (VRTX), BeOne Medicines Ltd. (ONC), and Royalty Pharma plc (RPRX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MRNA's relative position within its industry.

Frequently Asked Questions

The current stock price of Moderna (MRNA) is $199.30 in after-hours trading as of November 20, 2026.

The market cap of Moderna (MRNA) is approximately $80.6B. Learn more about what market capitalization means .

The FY2025 revenue of Moderna (MRNA) is $1.9B, from its most recent completed fiscal year.

The FY2025 net income of Moderna (MRNA) is -$2.8B, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Moderna (MRNA) is -$7.26 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Moderna (MRNA) is -$1.9B for FY2025, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of Moderna (MRNA) is 55.4% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Moderna (MRNA), current assets divided by current liabilities, was 3.29 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Moderna (MRNA) is $1.1B for FY2025, its most recent completed fiscal year.

The operating income of Moderna (MRNA) is -$3.1B for FY2025, its most recent completed fiscal year. Learn about operating income.

Moderna, Inc. develops medicines based on messenger RNA (mRNA). According to its public statements, the company’s mRNA platform has enabled vaccines and therapeutics across infectious diseases, cancer, rare diseases, latent and other viruses, and autoimmune diseases, and it has multiple approved products and an extensive clinical pipeline.

Moderna organizes its work into four franchises: respiratory virus vaccines, latent and other virus vaccines, oncology therapeutics and rare disease therapeutics. Its respiratory portfolio includes approved COVID-19 and RSV vaccines and late-stage candidates for seasonal influenza, a flu/COVID combination and Norovirus.

Moderna reports that its original COVID-19 vaccine Spikevax is approved in many countries, its RSV vaccine mRESVIA is approved in numerous countries for older adults and certain high-risk adults, and its new COVID-19 vaccine mNEXSPIKE has approvals in the U.S. and Canada, with filings in additional markets.

In oncology, Moderna is advancing mRNA-4157 (intismeran autogene) in collaboration with Merck in multiple Phase 2 and Phase 3 trials for tumor types such as melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma. It is also studying mRNA-4359, designed to elicit T-cell immune responses against tumor and immunosuppressive cells, in a Phase 1/2 trial.

Moderna highlights mRNA-3927, an investigational therapeutic for propionic acidemia in a registrational study, and mRNA-3705, an investigational therapeutic for methylmalonic acidemia that has been selected for the FDA’s START pilot program with a registrational study design agreed with the agency.

Moderna describes a global manufacturing network built around its mRNA platform. In the U.S., its Norwood, Massachusetts facility supports end-to-end production with automation, robotics and AI. The company has also added facilities in Canada, the UK and Australia to enable local access to mRNA medicines and support multi-year partnerships.

Moderna communicates a multi-year framework that includes driving sales of its existing products, advancing up to 10 products to approval in coming years, and achieving cost efficiencies across research and development, selling, general and administrative expenses, and cost of goods. It has stated a goal of reaching cash breakeven on a cash cost basis by 2028.

In November 2025, Moderna entered into a Credit and Guaranty Agreement for a credit facility of up to $1.5 billion, including an initial term loan and delayed draw term loans. The company describes this non-dilutive financing as bolstering its balance sheet and providing increased flexibility while it advances its late-stage clinical pipeline.

Moderna sought shareholder approval for a one-time stock option exchange program for non-Executive Committee employees to address underwater stock options. The company states that the program is intended to restore equity value for these employees, support retention and motivation, and better align employee and shareholder interests, while being designed to be fair-value neutral and anti-dilutive.

Moderna states that its mission is to deliver the greatest possible impact to people through mRNA medicines. It emphasizes a global team and a unique culture driven by company values and mindsets, and notes that it works at the intersection of science, technology and health to develop medicines at speed and scale.